Recent Quotes
My Watchlist
Indicators
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Business Exposures
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Kezar Life Sciences Stock Hit With Downgrades And Price Target Cuts: Retail Keeps Hopes Alive
Via Stocktwits
Topics Workforce
Tickers DFAS IWC KZR WFC
Exposures Layoff Product Safety
Why Is Taysha Gene Therapies Stock Falling Friday?
Via Benzinga
Tickers ALPMF ALPMY TSHA
Exposures Product Safety
CollaVita Collagen Announces Commitment to Quality Standards Through Third-Party Certifications
Via Press Advantage
Topics Supply Chain
Exposures Product Safety Supply Chain
CYTK INVESTOR ALERT: Bronstein, Gewirtz &amp; Grossman LLC Announces That Cytokinetics, Incorporated Investors With Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Via TheNewswire.com
Topics Fraud Lawsuit
Tickers CYTK
Exposures Financial Legal Product Safety
CYTK INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces That Cytokinetics, Incorporated Investors With Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Via NewMediaWire
Topics Fraud Lawsuit
Tickers CYTK
Exposures Financial Legal Product Safety
Artiva Biotherapeutics Gets A Price Target Hike From Wedbush: Stock Rallies 99% But Retail Expects Further Rally
Via Stocktwits
Tickers ARTV BIB IBBQ TSLA
Exposures Product Safety
Turnstone Biologics: A $100 Dream Collides with a $0.34 Reality
Via MarketMinute
Topics Intellectual Property Workforce
Tickers IOVA XOMA
Exposures Intellectual Property Layoff Product Safety
The FDA Just Granted Its Speediest Review Ever. Disc Medicine, Others Fly.
Via Investor's Business Daily
Tickers ACHV IRON REGN RVMD RY TSX:RY
Exposures Product Safety
FDA Unveils First Experimental Drugs Under Fast-Track Voucher Plan To Cut Drug Review Times
Via Benzinga
Tickers ACHV IRON MKGAF MKKGY REGN RVMD
Exposures Product Safety
Cytokinetics, Incorporated Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before November 17, 2025 to Discuss Your Rights - CYTK
Via NewMediaWire
Topics Earnings Fraud Lawsuit
Tickers CYTK
Exposures Financial Legal Product Safety
Levi & Korsinsky Notifies Shareholders of aTyr Pharma, Inc. (ATYR) of a Class Action Lawsuit and an Upcoming Deadline
Via NewMediaWire
Topics Fraud Lawsuit
Tickers ATYR
Exposures Financial Legal Product Safety
Levi &amp; Korsinsky Reminds Savara Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of November 7, 2025 - SVRA
Via TheNewswire.com
Topics Fraud Lawsuit
Tickers SVRA
Exposures Financial Legal Product Safety
Cytokinetics, Incorporated Securities Fraud Class Action Lawsuit Pending: Contact Levi &amp; Korsinsky Before November 17, 2025 to Discuss Your Rights - CYTK
Via TheNewswire.com
Topics Earnings Fraud Lawsuit
Tickers CYTK
Exposures Financial Legal Product Safety
Levi &amp; Korsinsky Notifies Shareholders of aTyr Pharma, Inc. (ATYR) of a Class Action Lawsuit and an Upcoming Deadline
Via TheNewswire.com
Topics Fraud Lawsuit
Tickers ATYR
Exposures Financial Legal Product Safety
Levi & Korsinsky Reminds Savara Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of November 7, 2025 - SVRA
Via NewMediaWire
Topics Fraud Lawsuit
Tickers SVRA
Exposures Financial Legal Product Safety
OS Therapies Granted Final Type C Meeting by U.S. FDA and pre-MAA Meeting by U.K. MHRA for OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma
Via Newsfile
Tickers OSTX
Exposures Product Safety
PharmaTher Applauds FDA's Commissioner's National Priority Voucher (CNPV) Selection of Ketamine; Company Highlights Potential Ketamine Opportunity, 505(b)(2) Focus, and Upside from Strategic ANDA Sale
Via Newsfile
Tickers CSE:PHRM PHRRF
Exposures Product Safety
Why Atai Life Sciences Stock Was So Lively This Week
Via The Motley Fool
Tickers ATAI
Exposures Product Safety
ABVC BioPharma Highlighted by U.S. Financial Media as One of the Best Biotech Investments; Q3 Licensing Revenue Reaches $1.27 Million, With Clear Clinical Progress Across CNS and Oncology
Via TheNewswire.com
Tickers ABVC
Exposures Product Safety
ABVC BioPharma Highlighted by U.S. Financial Media as One of the Best Biotech Investments; Q3 Licensing Revenue Reaches $1.27 Million, With Clear Clinical Progress Across CNS and Oncology
Via NewMediaWire
Tickers ABVC
Exposures Product Safety
Ford Issues Massive Recall Of Over 680,000 Vehicles Across Multiple Models: Here's What You Should Know
Via Benzinga
Topics Product Recall
Tickers F
Exposures Legal Product Safety
Revolution Medicines, Disc Medicine, Regeneron Stocks Jump After-Hours As FDA Fast-Tracks 9 Drugs Under New Review Program
Via Stocktwits
Tickers ACHV IRON LLY MRK REGN RVMD
Exposures Product Safety
Hope for Families Living With Familial Adenomatous Polyposis: A New FAP Clinical Trial is Now Enrolling
Via Press Release Distribution Service
Exposures Product Safety
Kenvue's Dual Dilemma: Tylenol and Talc Fears Trigger Sector Jitters
Via MarketMinute
Topics Death Government Lawsuit
Tickers JNJ KVUE
Exposures Death Financial Legal
Kenvue (KVUE) Plunges Amidst Dual Headwinds: Tylenol Fears and Escalating Talc Litigation
Via MarketMinute
Topics Government Lawsuit
Tickers JNJ KVUE
Exposures Financial Legal Political
Why Hims & Hers Health (HIMS) Shares Are Trading Lower Today
Via StockStory
Tickers BAC HIMS
Exposures Product Safety
US Government Shutdown: A Deep Dive into Market Volatility and Economic Strain
Via MarketMinute
Topics Bonds Economy Government
Tickers ADM BAH DAL DHI LMT MAR
Exposures Debt Markets Economy Interest Rates
MissionIRNewsBreaks – NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Advances KETAFREE(TM), Expands Pipeline Targeting Urgent Needs
Via Investor Brand Network
Tickers NRXP
Exposures Product Safety
Global Economy Braces for Impact as US-China Trade War Escalates Amidst Prolonged Government Shutdown
Via MarketMinute
Topics Economy Government Supply Chain
Tickers AAPL INTC JPM NVDA QCOM TSM
Exposures COVID-19 Economy Interest Rates
NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Pursues Dual Pathway for Preservative-Free Ketamine-Based Therapies
Via Investor Brand Network
Tickers NRXP
Exposures Product Safety
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.